Search Results for:
-
Clinic Roundup
Data also showed that the conjugated compound was absorbed following oral administration and metabolized to its active components intracellularly, providing proof of concept for the SMART Linker platformBioWorld Today | Tuesday, February 12, 2013 -
Other News To Note
Intellect Neurosciences Inc., of New York, said it started in vivo proof-of-concept studies for its monoclonal antibody, TauC3, in a preclinical model of Alzheimer's diseaseBioWorld Today | Friday, February 8, 2013 -
Other News To Note
Bone Medical Ltd., of Bentley, Australia, reported that its product candidate BN006 was found in a proof-of-concept study to reduce inflammation in a model of collagen antibody-induced arthritisBioWorld International | Wednesday, February 6, 2013 -
Research Alliance Seeks to Accelerate Drug Development
Unlike university research centers, which tend to operate as silos seeking to license or spin out home-grown discoveries, the alliance members are fully integrated translational medicine centers capable of advancing projects from discovery through preclinical screening to proof-of-concept studiesBy Marie Powers | BioWorld Today | Monday, February 4, 2013 -
Drug Discovery Alliance Aims To Boost Translational Hit Rate
While TransCelerate is seeking to improve the speed and quality of clinical trials by identifying and solving common bottlenecks in trial design and execution, the alliance hopes to advance more drug discovery projects through proof-of-concept by strengthening the international academic and not-for-profit drug development and commercialization network. (See BioWorld Today, Sept. 26, 2012.) Members of the alliance also have complementary strengthsBy Marie Powers | BioWorld Insight | Monday, February 4, 2013 -
Other News To Note
Bone Medical Ltd., of Bentley, Australia, reported that its product candidate BN006 was found in a proof-of-concept study to reduce inflammation in a model of collagen antibody-induced arthritisBioWorld Today | Wednesday, January 30, 2013 -
Other News To Note
The LDC will identify compounds and take the most promising into further drug discovery by optimizing them into pharmaceuticals leads with in vivo proof of conceptBioWorld International | Wednesday, January 30, 2013 -
Axerion Seeks New Answers in Spinal Cord Injury, Alzheimer's
A Phase I proof-of-concept study could recruit ASIA-A, B and C patients and then "be data-driven in terms of how we refine the patient population going forward" into pivotal trials, he saidBy Marie Powers | BioWorld Today | Monday, January 28, 2013 -
Anthera Approaches Phase III, Prices $40M Public Offering
Anthera is planning to begin enrollment in a Phase II proof-of-concept trial (BRIGHT-SC) in IgA nephropathy in 2013By Catherine Shaffer | BioWorld Today | Monday, January 28, 2013 -
Pharma: Other News To Note
The LDC will identify compounds and take the most promising into further drug discovery by optimizing them into pharmaceuticals leads with in vivo proof of conceptBioWorld Today | Monday, January 28, 2013 -
Clinic Roundup
Stratatech Corp., of Madison, Wis., reported top-line data from a proof-of-concept trial testing StrataGraft, a universal human skin substitute in development for treating severe burnsBioWorld Today | Thursday, January 17, 2013 -
DBV Seeks Immunotherapeutic to Desensitize Food Allergies
RSV Project: New Mechanism, Viaskin Delivery The RSV-NanoViaskin project with INRA aims to demonstrate preclinical proof of concept for a new model of pediatric RSV vaccine during a 30-month study in animal modelsBy Marie Powers | BioWorld Today | Wednesday, January 16, 2013 -
Versartis' $25M Series C to Fund HGH Trial in Children
Versartis is expecting proof-of-concept efficacy results from VERTICAL in 2014, at which time it will prepare for launch of a Phase III trialBy Catherine Shaffer | BioWorld Today | Wednesday, January 16, 2013 -
New Apoptosis-Targeting Drug Gets B Cells, Spares Platelets
Already, that has "allowed for a clinical proof of concept for selective BCL-2 inhibitionBy Anette Breindl | BioWorld Today | Friday, January 11, 2013 -
ISA Moving HPV Vaccine into Phase II with $10.5M Round
For us it was a very good clinical proof of concept," Mark Krul, the company's other joint managing director told BioWorld InternationalBy Cormac Sheridan | BioWorld International | Wednesday, January 9, 2013 -
Other News To Note
Addex Therapeutics SA, of Geneva, said it achieved preclinical proof of concept for its lead GABA-B receptor-positive allosteric modulator compound, ADX71441, in a model of Charcot-Marie-Tooth1A, a rare hereditary motor and sensory demyelinating peripheral neuropathy caused by an intrachromosomal duplication and consecutive toxic overexpression of the PMP22 gene on chromosome 17BioWorld International | Wednesday, January 9, 2013 -
Other News To Note
Under the terms, Daiichi will pay Amplimmune an undisclosed option fee and provide more than $50 million to reimburse past and planned R&D costs, including funding for future development through a Phase II proof-of-concept studyBioWorld Today | Wednesday, January 9, 2013 -
Other News To Note
Addex Therapeutics SA, of Geneva, said it achieved preclinical proof of concept for its lead GABA-B receptor-positive allosteric modulator compound, ADX71441, in a model of Charcot-Marie-Tooth1A, a rare hereditary motor and sensory demyelinating peripheral neuropathy caused by an intrachromosomal duplication and consecutive toxic overexpression of the PMP22 gene on chromosome 17BioWorld Today | Tuesday, January 8, 2013 -
ISA Moving HPV Vaccine into Phase II with $10.5M Round
For us it was a very good clinical proof of concept," Mark Krul, the company's other joint managing director told BioWorld TodayBy Cormac Sheridan | BioWorld Today | Tuesday, January 8, 2013 -
Milestone Payments From Corporate Partners: December 2012
proof of concept for the first DuoBody candidate 12/12/12 Halozyme Therapeutics Inc. (San Diego) Roche AG (Basel, Switzerland) $4 For the submission of a line extension application to the European Medicines Agency for a subcutaneous formulation of MabThera (rituximab) for non-Hodgkin's lymphoma 12/11/12 Millennium: The Takeda Oncology Company and Takeda Pharmaceutical CoBioWorld Insight | Monday, January 7, 2013
Category
Current Filters
- xproof of concept
Related Keywords
Categories
- x BioWorld Today (1420)
- x BioWorld International (480)
- x BioWorld Insight (188)
- x Bio Perspectives (72)
- x State of the Industry Report (24)
- x BioWorld Snapshots (15)
- x Biotech Innovations (13)
- x Top 25 Drug Report (4)
- x BioWorld Genomics Review (2)
- x Market-Leading Biotech Drugs (1)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.